Loading patent…
AssigneesFred Hutchinson Cancer Center, Memorial Sloan Kettering Cancer Center
InventorsJarrod Dudakov, Marcel van den Brink, Enrico Velardi, Hans-Peter Kiem, Stefan Radtke, Scott James
Estimating the term…
The use of luteinizing hormone receptor (LHR) binding agents and luteinizing hormone (LH) agonists to enrich for primitive hematopoietic stem cell (pHSC) populations, to target pHSC for ablation, and/or to expand pHSC populations are described. The methods can be used to prepare therapeutic hematopoietic stem cell (HSC) populations, to prepare patients for therapeutic HSC transplants, and/or to treat malignancies, such as those associated with hyperproliferative HSC.
1-94. (canceled)
A cDNA comprising SEQ ID NO:
A method of ablating primitive hematopoietic stem cells (pHSC) in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a pHSC-ablating agent comprising a luteinizing hormone receptor (LHR) binding agent.
Dependencies are inferred from the claim text.